HK1102423A1 - Muscarinic acetylcholine receptor antagonists - Google Patents

Muscarinic acetylcholine receptor antagonists

Info

Publication number: HK1102423A1
Authority: HK; Hong Kong
Prior art keywords: receptor antagonists; acetylcholine receptor; muscarinic acetylcholine; muscarinic; antagonists
Prior art date: 2004-04-27

Application number

HK07106891.0A

Other languages

English (en)

Inventor

Dramane I Laine

Michael R Palovich

Brent W Mccleland

Christopher E Neipp

Sonia M Thomas

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-27

Filing date

2007-06-27

Publication date

2007-11-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35242158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1102423(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-06-27 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2007-11-23 Publication of HK1102423A1 publication Critical patent/HK1102423A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Indole Compounds (AREA)

HK07106891.0A 2004-04-27 2007-06-27 Muscarinic acetylcholine receptor antagonists HK1102423A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US56562304P	2004-04-27	2004-04-27
PCT/US2005/014386 WO2005104745A2 (fr)	2004-04-27	2005-04-27	Antagonistes des récepteurs muscariniques de l'acétylcholine

Publications (1)

Publication Number	Publication Date
HK1102423A1 true HK1102423A1 (en)	2007-11-23

Family

ID=35242158

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK07106891.0A HK1102423A1 (en)	2004-04-27	2007-06-27	Muscarinic acetylcholine receptor antagonists

Country Status (38)

Country	Link
US (9)	US7498440B2 (fr)
EP (3)	EP2570128B1 (fr)
JP (2)	JP5014121B2 (fr)
KR (2)	KR101037026B1 (fr)
CN (2)	CN102040602A (fr)
AP (1)	AP2213A (fr)
AR (1)	AR050902A1 (fr)
AU (1)	AU2005237576B2 (fr)
BE (1)	BE2014C063I2 (fr)
BR (1)	BRPI0510170B8 (fr)
CA (2)	CA2755954C (fr)
CY (3)	CY1113196T1 (fr)
DK (2)	DK1740177T3 (fr)
EA (2)	EA021994B1 (fr)
EC (1)	ECSP066940A (fr)
ES (2)	ES2600405T3 (fr)
HK (1)	HK1102423A1 (fr)
HR (2)	HRP20120832T1 (fr)
HU (2)	HUE031304T2 (fr)
IL (1)	IL178152A (fr)
LT (1)	LT2570128T (fr)
LU (1)	LU92565I2 (fr)
MA (1)	MA28631B1 (fr)
MX (1)	MXPA06012405A (fr)
MY (1)	MY144753A (fr)
NL (1)	NL300694I2 (fr)
NO (3)	NO338959B1 (fr)
NZ (1)	NZ549997A (fr)
PE (1)	PE20060259A1 (fr)
PL (2)	PL2570128T3 (fr)
PT (2)	PT1740177E (fr)
SG (1)	SG186597A1 (fr)
SI (2)	SI2570128T1 (fr)
TW (1)	TWI363759B (fr)
UA (1)	UA95768C2 (fr)
UY (1)	UY28871A1 (fr)
WO (1)	WO2005104745A2 (fr)
ZA (1)	ZA200608565B (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200519108A (en) *	2003-07-17	2005-06-16	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
MXPA06004242A (es) *	2003-10-17	2006-06-28	Glaxo Group Ltd	Antagonistas del receptor muscarinico de la acetilcolina.
TW200524577A (en) *	2003-11-04	2005-08-01	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
EP1725236A4 (fr) *	2004-03-11	2009-05-13	Glaxo Group Ltd	Nouveaux antagonistes du recepteur de l'acetylcholine muscarinique m3
WO2005095407A1 (fr) *	2004-03-17	2005-10-13	Glaxo Group Limited	Antagonistes du recepteur d'acetylcholine muscarinique m3
US20070185148A1 (en) *	2004-03-17	2007-08-09	Glaxo Group Limited	M3 muscarinic acetylchoine receptor antagonists
DE602005009158D1 (de) *	2004-04-05	2008-10-02	Samaritan Pharmaceuticals Inc	Anti-hiv-chinuklidinverbindungen
AR050902A1 (es)	2004-04-27	2006-12-06	Glaxo Group Ltd	Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
JP2007537261A (ja) *	2004-05-13	2007-12-20	グラクソ　グループ　リミテッド	ムスカリン性アセチルコリン受容体アンタゴニスト
GB0424284D0 (en)	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
US7932247B2 (en) *	2004-11-15	2011-04-26	Glaxo Group Limited	M3 muscarinic acetylcholine receptor antagonists
EP1937267A4 (fr) *	2005-08-02	2009-08-26	Glaxo Group Ltd	Antagonistes des recepteurs de l' acetylcholine muscarinique m3
JP2009504768A (ja) *	2005-08-18	2009-02-05	グラクソグループリミテッド	ムスカリン性アセチルコリン受容体アンタゴニスト
KR20090003349A (ko)	2006-04-20	2009-01-09	글락소 그룹 리미티드	화합물
GB0611587D0 (en)	2006-06-12	2006-07-19	Glaxo Group Ltd	Novel compounds
DK2046787T3 (da)	2006-08-01	2011-07-18	Glaxo Group Ltd	Pyrazolo[3,4-B]pyridin-forbindelser, og deres anvendelse som PDE4-inhibitorer
AR065804A1 (es)	2007-03-23	2009-07-01	Smithkline Beecham Corp	Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
TW200946526A (en)	2008-02-06	2009-11-16	Glaxo Group Ltd	Dual pharmacophores-PDE4-muscarinic antagonistics
PE20091552A1 (es)	2008-02-06	2009-10-25	Glaxo Group Ltd	Farmacoforos duales - antagonistas muscarinicos de pde4
PE20091563A1 (es)	2008-02-06	2009-11-05	Glaxo Group Ltd	Farmacoforos duales - antagonistas muscarinicos de pde4
US8765743B2 (en)	2008-06-05	2014-07-01	Glaxosmithkline Intellectual Property Development Limited	Compounds
JP5502858B2 (ja)	2008-06-05	2014-05-28	グラクソグループリミテッド	Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
WO2010094643A1 (fr)	2009-02-17	2010-08-26	Glaxo Group Limited	Dérivés de quinoline et applications associées dans la rhinite et l'urticaire
PT2400950T (pt)	2009-02-26	2019-08-29	Glaxo Group Ltd	Formulações farmacêuticas compreendendo 4-{(1r)-2-[(6-{2-[(2,6-diclorobenzil)oxi]ethoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
EP2406255B1 (fr)	2009-03-09	2015-04-29	Glaxo Group Limited	4-oxadiazol-2-yl-indazoles en tant qu'inhibiteurs des pi3 kinases
EP2406249A1 (fr)	2009-03-10	2012-01-18	Glaxo Group Limited	Dérivés d'indole comme inhibiteurs de ikk2
US20120058984A1 (en)	2009-03-17	2012-03-08	Catherine Mary Alder	Pyrimidine derivatives used as itk inhibitors
KR101771193B1 (ko)	2009-04-30	2017-09-05	글락소 그룹 리미티드	Ｐｉ3키나아제 억제제로서 옥사졸 치환된 인다졸
WO2011029896A1 (fr)	2009-09-11	2011-03-17	Glaxo Group Limited	Procedes de preparation d'antagonistes des recepteurs cholinergiques muscariniques
GB0921075D0 (en) *	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents
US20120238571A1 (en)	2009-12-03	2012-09-20	Glaxo Group Limited	Indazole derivatives as pi 3-kinase
US20120245171A1 (en)	2009-12-03	2012-09-27	Glaxo Group Limited	Benzpyrazole derivatives as inhibitors of pi3 kinases
JP2013512878A (ja)	2009-12-03	2013-04-18	グラクソグループリミテッド	新規化合物
ES2655083T3 (es) *	2010-01-28	2018-02-16	Theron Pharmaceuticals, Inc.	Derivados de 7-azoniabiciclo [2.2.1]heptano, métodos de producción, y usos farmacéuticos de estos
WO2011110575A1 (fr)	2010-03-11	2011-09-15	Glaxo Group Limited	Dérivés de 2-[2-(benzo- ou pyrido-)thiazolylamino]-6- aminopyridine, utiles dans le traitement de maladies respiratoires, allergiques ou inflammatoires
WO2011160920A1 (fr) *	2010-06-22	2011-12-29	Chiesi Farmaceutici S.P.A.	Formulation de poudre sèche comprenant un médicament antimuscarinique
WO2012032067A1 (fr)	2010-09-08	2012-03-15	Glaxo Group Limited	Polymorphes et sels de n-[5-[4-(5-{[(2r,6s-2,6-diméthyl-4-morpholinyl]- méthyl}-1,3-oxazol-2-yl)-1h-indazol-6-yl]-2-(méthyloxy)-3-pyridinyl]- méthanesulfonamide
WO2012035055A1 (fr)	2010-09-17	2012-03-22	Glaxo Group Limited	Nouveaux composés
GB201018124D0 (en)	2010-10-27	2010-12-08	Glaxo Group Ltd	Polymorphs and salts
KR20140041700A (ko)	2011-06-08	2014-04-04	글락소 그룹 리미티드	우메클리디늄을 포함하는 건조 분말 흡입기 조성물
SG195262A1 (en)	2011-06-08	2013-12-30	Glaxo Group Ltd	Combination comprising umeclidinium and a corticosteroid
RU2666963C2 (ru)	2012-04-13	2018-09-13	Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед	Агрегированные частицы
RU2502743C1 (ru) *	2012-08-03	2013-12-27	Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России)	Синтетический антиген, обладающий способностью связывать аутоантитела к мускариновому м2-рецептору
EP2885298B1 (fr) *	2012-08-15	2018-06-13	Glaxo Group Limited	Processus chimique
GB201222679D0 (en) *	2012-12-17	2013-01-30	Glaxo Group Ltd	Pharmaceutical combination products
RU2641285C2 (ru)	2013-07-13	2018-01-17	Бэйцзин Фсвэлкам Текнолоджи Девелопмент Ко., Лтд	Соединения хинина, способ их получения и их медицинское применение
PE20160198A1 (es) *	2013-07-30	2016-04-21	Glaxosmithkline Ip Dev Ltd	Composiciones topicas para el tratamiento de sudoracion excesiva y metodos para utilizar las mismas
WO2015055691A1 (fr)	2013-10-17	2015-04-23	Glaxosmithkline Intellectual Property Development Limited	Inhibiteur de pi3k pour le traitement d'une maladie respiratoire
CA2923995A1 (fr)	2013-10-17	2015-04-23	Glaxosmithkline Intellectual Property Development Limited	Inhibiteur de pi3k pour le traitement d'une maladie respiratoire
EP3142694A2 (fr)	2014-05-12	2017-03-22	Glaxosmithkline Intellectual Property (No. 2) Limited	Compositions pharmaceutiques comprenant danirixin pour traiter des maladies infecteuses
EP3650019B8 (fr)	2014-05-28	2023-10-11	GlaxoSmithKline Intellectual Property Development Limited	Furoate de fluticasone utilisé dans le traitement de la bpco
JP6615212B2 (ja) *	2014-11-03	2019-12-04	オロンソシエタペルアチオニ	１−（２−ハロゲン−エチル）−４−ピぺリジンカルボン酸エチルエステルの製法
KR101613245B1 (ko)	2015-04-27	2016-04-18	주식회사 대웅제약	신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN105461710A (zh) *	2015-10-23	2016-04-06	安徽德信佳生物医药有限公司	一种芜地溴铵的制备方法
GB201602527D0 (en)	2016-02-12	2016-03-30	Glaxosmithkline Ip Dev Ltd	Chemical compounds
CN107200734B (zh) *	2016-03-18	2019-12-24	益方生物科技（上海）有限公司	奎宁环衍生物及其制备方法和用途
EP3248970A1 (fr)	2016-05-27	2017-11-29	Zentiva K.S.	Les formes du bromure d'uméclidinium
EP3497100A1 (fr)	2016-08-08	2019-06-19	GlaxoSmithKline Intellectual Property Development Limited	Composés chimiques
PT109740B (pt)	2016-11-14	2020-07-30	Hovione Farmaciencia Sa	Processo para a preparação de brometo de umeclidínio
WO2018163212A1 (fr) *	2017-03-08	2018-09-13	Gbr Laboratories Pvt. Ltd	Procédé de préparation de bromure d'uméclidinium et de ses intermédiaires
GB201706102D0 (en)	2017-04-18	2017-05-31	Glaxosmithkline Ip Dev Ltd	Chemical compounds
IT201700058796A1 (it) *	2017-05-30	2018-11-30	Olon Spa	Procedimento per la preparazione di un nuovo intermedio di sintesi dell’umeclidinio.
GB201712081D0 (en)	2017-07-27	2017-09-13	Glaxosmithkline Ip Dev Ltd	Chemical compounds
CN108558860B (zh) *	2018-06-04	2020-12-25	成都伊诺达博医药科技有限公司	一种合成芜地溴铵的方法
US11484531B2 (en)	2018-08-30	2022-11-01	Theravance Biopharma R&D Ip, Llc	Methods for treating chronic obstructive pulmonary disease
PT115583B (pt)	2019-06-17	2022-05-02	Hovione Farm S A	Processo contínuo para a preparação de medicamentos anticolinérgicos
CN113387923A (zh) *	2020-03-13	2021-09-14	诺华股份有限公司	硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
EP4125919A1 (fr)	2020-03-26	2023-02-08	GlaxoSmithKline Intellectual Property Development Limited	Inhibiteurs de cathepsine pour la prévention ou le traitement d'infections virales
CN111484445B (zh) *	2020-04-21	2021-05-18	广东莱佛士制药技术有限公司	分离纯化高纯度乌美溴铵的中间体的方法
EP4144733A4 (fr) *	2020-04-26	2024-05-15	Beijing Showby Pharmaceutical Co., Ltd.	Cristal de l'antagoniste du récepteur m, son procédé de préparation et son utilisation
WO2022053651A2 (fr)	2020-09-10	2022-03-17	Precirix N.V.	Fragment d'anticorps contre fap
CN112479983B (zh) *	2020-11-25	2022-07-12	江苏豪森药业集团有限公司	乌美溴铵中间体及其制备方法
PT117440B (pt)	2021-09-03	2024-04-26	Hovione Farm S A	Processo para a preparação de aminas cíclicas cloroaquilo substituídas
WO2023203135A1 (fr)	2022-04-22	2023-10-26	Precirix N.V.	Anticorps radiomarqué amélioré
WO2023213801A1 (fr)	2022-05-02	2023-11-09	Precirix N.V.	Pré-ciblage

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2800481A (en) *	1955-07-01	1957-07-23	Smith Kline French Lab	Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800478A (en) *	1955-07-01	1957-07-23	Smith Kline French Lab	3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (de) *	1967-06-08	1972-04-25	Siemens Ag	Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens
GB1242211A (en)	1967-08-08	1971-08-11	Fisons Pharmaceuticals Ltd	Pharmaceutical composition
GB1230087A (fr)	1967-08-17	1971-04-28
GB1381872A (en)	1971-06-22	1975-01-29	Fisons Ltd	Pharmaceutical compositions for inhalation
CY1308A (en)	1979-12-06	1985-12-06	Glaxo Group Ltd	Device for dispensing medicaments
ATE23272T1 (de)	1981-07-08	1986-11-15	Draco Ab	Pulverinhalator.
GB2169265B (en)	1982-10-08	1987-08-12	Glaxo Group Ltd	Pack for medicament
CA1224992A (fr)	1982-10-08	1987-08-04	Robert E. Newell	Dispositif pour l'administration d'un medicament a un patient
IE59026B1 (en)	1985-07-30	1993-12-15	Glaxo Group Ltd	Devices for administering medicaments to patients
IT1204826B (it)	1986-03-04	1989-03-10	Chiesi Farma Spa	Composizioni farmaceutiche per inalazione
GB9004781D0 (en)	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
US5780466A (en) *	1995-01-30	1998-07-14	Sanofi	Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
US6350758B1 (en) *	1996-12-02	2002-02-26	Georgetown University	Tropane derivatives and method for their synthesis
US6248752B1 (en) *	1998-02-27	2001-06-19	Charles Duane Smith	Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) *	1998-07-27	2001-07-17	Schering Corporation	High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (es)	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ES2266291T3 (es) *	2000-12-28	2007-03-01	Almirall Prodesfarma Ag	Nuevos derivados de quinuclidina y composiciones medicinales que los contienen.
CN1571787A (zh) *	2001-10-17	2005-01-26	Ucb公司	奎宁环衍生物、制备它们的方法和它们作为m2和/或m3毒蕈碱受体抑制剂的用途
US6951868B2 (en) *	2001-11-09	2005-10-04	Pfizer Inc.	Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease
MXPA04006206A (es) *	2001-12-20	2004-12-06	S A L V A T Lab Sa	Derivados de 1-alquil-azoniabiciclo(2.2.2(octano carbamato y su uso como antagonistas del receptor musrcarinico.
US6696462B2 (en) *	2002-01-31	2004-02-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
ES2206021B1 (es)	2002-04-16	2005-08-01	Almirall Prodesfarma, S.A.	Nuevos derivados de pirrolidinio.
ES2204295B1 (es) *	2002-07-02	2005-08-01	Almirall Prodesfarma, S.A.	Nuevos derivados de quinuclidina-amida.
AR040779A1 (es)	2002-08-06	2005-04-20	Glaxo Group Ltd	Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion
US7232841B2 (en)	2003-04-07	2007-06-19	Glaxo Group Limited	M3 muscarinic acetylcholine receptor antagonists
TW200519109A (en)	2003-07-17	2005-06-16	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
TW200519108A (en)	2003-07-17	2005-06-16	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
PE20050327A1 (es)	2003-07-17	2005-06-08	Glaxo Group Ltd	Derivados de 8-azoniabiciclo[3.2.1]octano como antagonistas de los receptores muscarinicos de la acetilcolina
NZ546312A (en)	2003-10-14	2008-09-26	Glaxo Group Ltd	Muscarinic acetycholine receptor antagonists
MXPA06004242A (es)	2003-10-17	2006-06-28	Glaxo Group Ltd	Antagonistas del receptor muscarinico de la acetilcolina.
TW200524577A (en)	2003-11-04	2005-08-01	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
DE602004021959D1 (de) *	2003-11-21	2009-08-20	Theravance Inc	Verbindungen mit agonistischer wirkung am beta2-adrenergen rezeptor und am muscarinischen rezeptor
UY28646A1 (es)	2003-12-03	2005-06-30	Glaxo Group Ltd	Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
AR046784A1 (es)	2003-12-03	2005-12-21	Glaxo Group Ltd	Compuesto de amina ciclica composicion farmaceutica que lo comprende y su uso para preparar esta ultima
TW200534855A (en)	2004-01-13	2005-11-01	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
EP1725236A4 (fr)	2004-03-11	2009-05-13	Glaxo Group Ltd	Nouveaux antagonistes du recepteur de l'acetylcholine muscarinique m3
US20070179131A1 (en)	2004-03-11	2007-08-02	Jian Jin	Novel M3 Muscarinic Acetylcholine Receptor Antagonists
US20070185148A1 (en)	2004-03-17	2007-08-09	Glaxo Group Limited	M3 muscarinic acetylchoine receptor antagonists
JP2007529512A (ja)	2004-03-17	2007-10-25	グラクソ　グループ　リミテッド	ムスカリン性アセチルコリン受容体アンタゴニスト
WO2005095407A1 (fr)	2004-03-17	2005-10-13	Glaxo Group Limited	Antagonistes du recepteur d'acetylcholine muscarinique m3
EP1725241A4 (fr)	2004-03-17	2009-03-25	Glaxo Group Ltd	Antagonistes du recepteur d'acetylcholine muscarinique m3
EP1732923A2 (fr)	2004-04-07	2006-12-20	Glaxo Group Limited	Antagonistes du recepteur muscarinique de l'acetylcholine
AR050902A1 (es)	2004-04-27	2006-12-06	Glaxo Group Ltd	Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
JP2007537261A (ja)	2004-05-13	2007-12-20	グラクソ　グループ　リミテッド	ムスカリン性アセチルコリン受容体アンタゴニスト
US7579345B2 (en)	2004-05-28	2009-08-25	Glaxo Group Limited	Muscarinic acetylcholine receptor antagonists
WO2006005057A2 (fr)	2004-06-30	2006-01-12	Glaxo Group Limited	Antagonistes du recepteur muscarinique d'acetylcholine
JP2008509159A (ja)	2004-08-05	2008-03-27	グラクソグループリミテッド	ムスカリン性アセチルコリン受容体拮抗薬
US20090076061A1 (en)	2004-08-06	2009-03-19	Jakob Busch-Petersen	Muscarinic acetycholine receptor antagonists
WO2006050239A2 (fr)	2004-10-29	2006-05-11	Glaxo Group Limited	Antagonistes des recepteurs de l'acetylcholine muscarinique
US20090142279A1 (en)	2004-11-15	2009-06-04	Budzik Brian W	Novel m3 muscarinic acetylcholine receptor antagonists
US7932247B2 (en)	2004-11-15	2011-04-26	Glaxo Group Limited	M3 muscarinic acetylcholine receptor antagonists
PE20060826A1 (es)	2004-12-06	2006-10-08	Smithkline Beecham Corp	Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
PE20061162A1 (es)	2004-12-06	2006-10-14	Smithkline Beecham Corp	Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
WO2006065755A2 (fr)	2004-12-13	2006-06-22	Glaxo Group Limited	Sels d'ammonium quaternaire d'amines heteroaromatiques fusionnees utilises comme nouveaux antagonistes du recepteur de l'acetylcholine muscarinique
WO2006065788A2 (fr)	2004-12-13	2006-06-22	Glaxo Group Limited	Nouveaux antagonistes du recepteur muscarinique de l'acetylcholine
WO2007018514A1 (fr)	2005-07-28	2007-02-15	Glaxo Group Limited	Nouveaux antagonistes récepteurs d’acétylcholine muscarinique m3
WO2007018508A1 (fr)	2005-07-28	2007-02-15	Glaxo Group Limited	Nouveaux antagonistes du récepteur muscarinique m3 de l’acétylcholine
EP1937267A4 (fr)	2005-08-02	2009-08-26	Glaxo Group Ltd	Antagonistes des recepteurs de l' acetylcholine muscarinique m3
WO2007016650A2 (fr)	2005-08-02	2007-02-08	Glaxo Group Limited	Antagonistes du recepteur d'acetylcholine muscarinique m3
JP2009504768A (ja)	2005-08-18	2009-02-05	グラクソグループリミテッド	ムスカリン性アセチルコリン受容体アンタゴニスト
GB0921075D0 (en) *	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents

2005
- 2005-04-25 AR ARP050101627A patent/AR050902A1/es active IP Right Grant
- 2005-04-25 PE PE2005000457A patent/PE20060259A1/es active IP Right Grant
- 2005-04-25 UY UY28871A patent/UY28871A1/es not_active Application Discontinuation
- 2005-04-25 MY MYPI20051806A patent/MY144753A/en unknown
- 2005-04-25 TW TW094113034A patent/TWI363759B/zh active
- 2005-04-27 JP JP2007510915A patent/JP5014121B2/ja active Active
- 2005-04-27 PL PL12170402T patent/PL2570128T3/pl unknown
- 2005-04-27 KR KR1020067022276A patent/KR101037026B1/ko active Protection Beyond IP Right Term
- 2005-04-27 KR KR1020117001909A patent/KR101152032B1/ko active IP Right Grant
- 2005-04-27 PT PT05746609T patent/PT1740177E/pt unknown
- 2005-04-27 AP AP2006003746A patent/AP2213A/xx active
- 2005-04-27 PT PT121704027T patent/PT2570128T/pt unknown
- 2005-04-27 SI SI200532099A patent/SI2570128T1/sl unknown
- 2005-04-27 CN CN2010105580787A patent/CN102040602A/zh active Pending
- 2005-04-27 EP EP12170402.7A patent/EP2570128B1/fr active Active
- 2005-04-27 US US11/568,330 patent/US7498440B2/en active Active
- 2005-04-27 PL PL05746609T patent/PL1740177T3/pl unknown
- 2005-04-27 MX MXPA06012405A patent/MXPA06012405A/es active IP Right Grant
- 2005-04-27 EP EP05746609A patent/EP1740177B1/fr active Active
- 2005-04-27 DK DK05746609.6T patent/DK1740177T3/da active
- 2005-04-27 CA CA2755954A patent/CA2755954C/fr active Active
- 2005-04-27 LT LTEP12170402.7T patent/LT2570128T/lt unknown
- 2005-04-27 UA UAA200611253A patent/UA95768C2/ru unknown
- 2005-04-27 EP EP16177012.8A patent/EP3111936A1/fr not_active Withdrawn
- 2005-04-27 SI SI200531605T patent/SI1740177T1/sl unknown
- 2005-04-27 ES ES12170402.7T patent/ES2600405T3/es active Active
- 2005-04-27 DK DK12170402.7T patent/DK2570128T3/en active
- 2005-04-27 SG SG2012087052A patent/SG186597A1/en unknown
- 2005-04-27 EA EA201100019A patent/EA021994B1/ru not_active IP Right Cessation
- 2005-04-27 NZ NZ549997A patent/NZ549997A/en unknown
- 2005-04-27 AU AU2005237576A patent/AU2005237576B2/en active Active
- 2005-04-27 EA EA200601991A patent/EA015033B1/ru not_active IP Right Cessation
- 2005-04-27 HU HUE12170402A patent/HUE031304T2/hu unknown
- 2005-04-27 CN CNA2005800215360A patent/CN1976701A/zh active Pending
- 2005-04-27 BR BRPI0510170A patent/BRPI0510170B8/pt active IP Right Grant
- 2005-04-27 WO PCT/US2005/014386 patent/WO2005104745A2/fr active Application Filing
- 2005-04-27 ES ES05746609.6T patent/ES2392848T4/es active Active
- 2005-04-27 CA CA2564742A patent/CA2564742C/fr active Active
2006
- 2006-09-18 IL IL178152A patent/IL178152A/en active Protection Beyond IP Right Term
- 2006-10-13 ZA ZA2006/08565A patent/ZA200608565B/en unknown
- 2006-10-20 EC EC2006006940A patent/ECSP066940A/es unknown
- 2006-10-31 MA MA29426A patent/MA28631B1/fr unknown
- 2006-11-24 NO NO20065417A patent/NO338959B1/no active Protection Beyond IP Right Term
2007
- 2007-06-27 HK HK07106891.0A patent/HK1102423A1/xx unknown
- 2007-07-09 US US11/774,867 patent/US7488827B2/en active Active
2009
- 2009-01-14 US US12/353,436 patent/US8183257B2/en active Active
2012
- 2012-02-22 US US13/401,890 patent/US8309572B2/en active Active
- 2012-04-13 JP JP2012092339A patent/JP5398871B2/ja active Active
- 2012-09-26 US US13/627,007 patent/US8575347B2/en active Active
- 2012-10-15 HR HRP20120832TT patent/HRP20120832T1/hr unknown
- 2012-10-17 CY CY20121100965T patent/CY1113196T1/el unknown
2013
- 2013-10-14 US US14/052,816 patent/US8853404B2/en active Active
2014
- 2014-09-04 US US14/476,940 patent/US9045469B2/en active Active
- 2014-09-26 HU HUS1400053C patent/HUS1400053I1/hu unknown
- 2014-10-02 BE BE2014C063C patent/BE2014C063I2/fr unknown
- 2014-10-02 LU LU92565C patent/LU92565I2/fr unknown
- 2014-10-02 NL NL300694C patent/NL300694I2/nl unknown
- 2014-10-03 CY CY2014043C patent/CY2014043I2/el unknown
2015
- 2015-05-08 US US14/707,543 patent/US9144571B2/en active Active
- 2015-09-10 US US14/849,775 patent/US20160002220A1/en not_active Abandoned
2016
- 2016-10-10 CY CY20161101008T patent/CY1118082T1/el unknown
- 2016-10-25 HR HRP20161385TT patent/HRP20161385T1/hr unknown
2017
- 2017-05-04 NO NO2017017C patent/NO2017017I1/no unknown
- 2017-05-04 NO NO2017018C patent/NO2017018I2/no unknown

Also Published As

Publication number	Publication date
IL178152A0 (en)	2006-12-31
PL2570128T3 (pl)	2017-09-29
EA015033B1 (ru)	2011-04-29
EP1740177A4 (fr)	2010-05-05
EP1740177B1 (fr)	2012-08-08
CN1976701A (zh)	2007-06-06
KR101037026B1 (ko)	2011-05-25
NO2017017I1 (no)	2017-05-04
EP3111936A1 (fr)	2017-01-04
HRP20161385T1 (hr)	2016-12-02
US8853404B2 (en)	2014-10-07
BRPI0510170B8 (pt)	2021-05-25
WO2005104745A2 (fr)	2005-11-10
US20090124653A1 (en)	2009-05-14
IL178152A (en)	2011-05-31
BE2014C063I2 (fr)	2024-08-08
WO2005104745A3 (fr)	2006-08-03
EA021994B1 (ru)	2015-10-30
US20130030015A1 (en)	2013-01-31
NL300694I1 (fr)	2015-12-29
PE20060259A1 (es)	2006-03-25
US8575347B2 (en)	2013-11-05
UY28871A1 (es)	2005-11-30
US9144571B2 (en)	2015-09-29
KR101152032B1 (ko)	2012-06-11
US20070249664A1 (en)	2007-10-25
US20140080863A1 (en)	2014-03-20
HRP20120832T1 (hr)	2012-11-30
CA2564742C (fr)	2012-01-10
TWI363759B (en)	2012-05-11
KR20070015412A (ko)	2007-02-02
JP5398871B2 (ja)	2014-01-29
MXPA06012405A (es)	2007-01-17
KR20110010841A (ko)	2011-02-07
CY1118082T1 (el)	2017-06-28
US20160002220A1 (en)	2016-01-07
DK2570128T3 (en)	2016-11-07
LU92565I2 (fr)	2014-12-02
SI2570128T1 (sl)	2016-11-30
NO338959B1 (no)	2016-11-07
AP2006003746A0 (en)	2006-10-31
CY2014043I1 (el)	2015-12-09
JP2012162559A (ja)	2012-08-30
US7498440B2 (en)	2009-03-03
JP5014121B2 (ja)	2012-08-29
NO2017018I2 (no)	2018-05-14
HUS1400053I1 (hu)	2017-07-28
ES2600405T3 (es)	2017-02-08
EP2570128B1 (fr)	2016-08-10
US7488827B2 (en)	2009-02-10
NO2017018I1 (no)	2017-05-04
TW200605887A (en)	2006-02-16
EA200601991A1 (ru)	2007-02-27
CA2564742A1 (fr)	2005-11-10
EP2570128A1 (fr)	2013-03-20
US8183257B2 (en)	2012-05-22
CY1113196T1 (el)	2015-12-09
AU2005237576A1 (en)	2005-11-10
DK1740177T3 (da)	2012-10-29
US20120157491A1 (en)	2012-06-21
AU2005237576B2 (en)	2012-01-12
JP2007534769A (ja)	2007-11-29
ES2392848T3 (es)	2012-12-14
LU92565I9 (fr)	2019-01-17
US20070185155A1 (en)	2007-08-09
AR050902A1 (es)	2006-12-06
NL300694I2 (fr)	2015-12-29
MY144753A (en)	2011-10-31
CN102040602A (zh)	2011-05-04
BRPI0510170A (pt)	2007-10-02
MA28631B1 (fr)	2007-06-01
SG186597A1 (en)	2013-01-30
EA201100019A1 (ru)	2011-12-30
LT2570128T (lt)	2016-10-10
US8309572B2 (en)	2012-11-13
PT2570128T (pt)	2016-10-07
CA2755954C (fr)	2014-02-18
BRPI0510170B1 (pt)	2018-12-18
US20140371264A1 (en)	2014-12-18
UA95768C2 (ru)	2011-09-12
US20150238470A1 (en)	2015-08-27
NZ549997A (en)	2010-10-29
ES2392848T4 (es)	2014-10-01
CA2755954A1 (fr)	2005-11-10
CY2014043I2 (el)	2015-12-09
ZA200608565B (en)	2019-12-18
PL1740177T3 (pl)	2012-12-31
NO20065417L (no)	2006-12-29
SI1740177T1 (sl)	2012-12-31
PT1740177E (pt)	2012-11-02
EP1740177A2 (fr)	2007-01-10
US9045469B2 (en)	2015-06-02
HUE031304T2 (hu)	2017-07-28
AP2213A (en)	2011-03-01
ECSP066940A (es)	2006-12-20

Publication	Publication Date	Title
HUS1400053I1 (hu)	2017-07-28	Muszkarin acetilkolin receptor antagonisták
IL176775A0 (en)	2006-10-31	Muscarinic acetylcholine receptor antagonists
IL188112A0 (en)	2008-03-20	Muscarinic acetylcholine receptor antagonists
EP1725240A4 (fr)	2009-03-25	Antagonistes du recepteur d'acetylcholine muscarinique
EP1937068A4 (fr)	2010-08-04	Antagonistes de recepteurs d'acetylcholine muscarinique
EP1682142A4 (fr)	2009-11-25	Antagonistes du recepteur muscarinique m3 de l'acetylcholine
ZA200602783B (en)	2007-11-28	Muscarinic acetylcholine receptor antagonists
EP1725238A4 (fr)	2009-04-01	Antagonistes du recepteur muscarinique a l'acetylcholine m 3
EP1937267A4 (fr)	2009-08-26	Antagonistes des recepteurs de l' acetylcholine muscarinique m3
EP1937230A4 (fr)	2009-08-26	Antagonistes du recepteur d'acetylcholine muscarinique m3
EP1725236A4 (fr)	2009-05-13	Nouveaux antagonistes du recepteur de l'acetylcholine muscarinique m3
EP1648460A4 (fr)	2009-04-01	Antagonistes du recepteur de l'acetylcholine muscarinique
IL172911A0 (en)	2006-06-11	Muscarinic acetylcholine receptor antagonists
EP1957075A4 (fr)	2009-11-18	Nouveaux antagonistes des recepteurs muscariniques de type m3 de l'acetylcholine
IL172912A0 (en)	2006-06-11	Muscarinic acetylcholine receptor antagonists
EP1749012A4 (fr)	2009-07-29	Antagonistes du recepteur d'acetylcholine muscarinique
EP1824483A4 (fr)	2009-11-04	Antagonistes des recepteurs de l'acetylcholine muscarinique
EP1827439A4 (fr)	2009-11-18	Nouveaux antagonistes du recepteur d'acetylcholine muscarinique m3
EP1725241A4 (fr)	2009-03-25	Antagonistes du recepteur d'acetylcholine muscarinique m3
EP1725564A4 (fr)	2007-09-12	Antagonistes du recepteur d'acetylcholine muscarinique m3
EP1765339A4 (fr)	2009-09-02	Antagonistes du recepteur muscarinique d'acetylcholine
EP1781104A4 (fr)	2008-05-21	Antagonistes du recepteur d'acetylcholine muscarinique
EP1781103A4 (fr)	2008-05-14	Antagonistes du recepteur d'acetylcholine muscarinique
EP1751089A4 (fr)	2010-03-10	Nouveaux antagonistes du recepteur d'acetylcholine muscarinique m3
AP2008004537A0 (en)	2008-08-31	Muscarinic receptor antagonists